Clinical Trial Detail

NCT ID NCT02542293
Title Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE). (NEPTUNE)
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors AstraZeneca

lung non-small cell carcinoma


Cisplatin + Gemcitabine

Carboplatin + Gemcitabine

Durvalumab + Tremelimumab

Carboplatin + Paclitaxel

Cisplatin + Pemetrexed Disodium

Carboplatin + Pemetrexed Disodium

Age Groups: adult senior

Additional content available in CKB BOOST